Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

By developing dihydropyridinophthalazine compounds as PARP inhibitors, the problem of poor PARP activity in the prior art was solved, and effective therapeutic effects in a variety of diseases were achieved, especially in cancer and inflammatory diseases. The treatment intensifies.

CN103896942AInactive Publication Date: 2014-07-02MEDIVATION TECHNOLOGIES INC
6 Cites 3 Cited by

Patent Information

Application Number
CN201410003342.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2009-04-27
Filing Date
2009-07-27
Publication Date
2014-07-02
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively regulate the activity of poly(ADP-ribose) polymerase (PARP), resulting in poor effectiveness in treating PARP-related diseases.

Method used

Dihydropyridinophthalazine compounds with the structures of formula (I) and formula (II) have been developed as inhibitors of PARP for modulating the activity of PARP and in combination with ionizing radiation or chemotherapeutic agents to treat cancer.

Benefits of technology

These compounds effectively inhibit PARP, improve the therapeutic effects of a variety of diseases, including acute treatment of cytotoxicity after vascular diseases, inflammatory diseases, cancer and cardiovascular surgery, enhance the efficacy of chemotherapy, and reduce the metastasis and apoptosis of cancer cells Death.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined in the description. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
Need to check novelty before this filing date? Find Prior Art